Pfizer’s Xeljanz Has Strong Launch in Arthritis, May See Greater than Expected First-Line Use
Pfizer’s novel rheumatoid arthritis drug (RA) Xeljanz has had a strong launch in the U.S. Initial analysis of prescription data from Symphony Health Solutions suggests that Xeljanz use will not be limited to patients who have an inadequate response to TNF inhibitors, which currently dominate the market.
Additional data on a higher dose and use in an earlier stage of treatment may further improve launch metrics. The drug may also soon receive an opinion regarding EU approval.